Which of the following is NOT a common IV HEC drug?

Epirubicin is not a common intravenous highly emetogenic chemotherapy (HEC) drug. HEC drugs are known for their high potential to cause nausea and vomiting during chemotherapy treatment. While epirubicin is an effective chemotherapy agent primarily used to treat breast cancer and other malignancies, it is generally classified as a moderately emetogenic drug rather than a highly emetogenic one.

On the other hand, the other drugs listed—mechlorethamine, cyclophosphamide, and streptozocin—are classified as highly emetogenic. Mechlorethamine is a classic alkylating agent often used in the treatment of various lymphomas and leukemias, known for its substantial risk of inducing nausea and vomiting. Cyclophosphamide is a widely used alkylating agent that also has a significant emetic potential, particularly in higher doses. Streptozocin is recognized for its use in pancreatic neuroendocrine tumors and is associated with a high incidence of emesis as well.

Understanding the classification of these drugs is crucial for proper patient management, particularly in anticipating and mitigating potential side effects associated with chemotherapy.